adenosine monophosphate has been researched along with Pituitary Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camden, JM; Kerley, MS; Larson, BT; Paterson, JA; Piper, EL; Samford, MD; Turner, JT | 1 |
| Davies, JS; Ham, J; Lewis, MD; Scanlon, MF; Webster, J | 1 |
2 other study(ies) available for adenosine monophosphate and Pituitary Neoplasms
| Article | Year |
|---|---|
Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells.
Topics: Adenosine Monophosphate; Animals; Cell Membrane; Ergotamines; Pituitary Neoplasms; Radioligand Assay; Rats; Receptors, Dopamine D2; Second Messenger Systems; Sulpiride; Transfection; Tumor Cells, Cultured; Vasoactive Intestinal Peptide; Vasoconstrictor Agents | 1995 |
AMP is a component of the low molecular weight mitogenic activity present in human pituitary tumours.
Topics: Adenosine Monophosphate; Animals; Cell Line; Chromatography, Gel; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Mitogens; Molecular Weight; Pituitary Neoplasms; Rats; Thymidine; Tissue Extracts | 1996 |